Search Within

Michael Morris

  1. "Glenn Heller"
Formats
  1. Journal Article (30)
  2. Meeting Abstract (24)
Groups
  1. Biostatistics Service (54)
  2. Department of Medicine (54)
  3. Epidemiology and Biostatistics (54)
  4. Genitourinary Oncology Service (54)
  5. Solid Tumor Oncology Division (54)
  6. Radiology, Department of (21)

More Groups

People
  1. Glenn Heller (54)
  2. Howard Scher (34)
  3. Steven Larson (16)
  4. Susan Slovin (16)
  5. Dana Rathkopf (10)
  6. Lawrence Schwartz (8)

More People

Years
  1. 2025 (1)
  2. 2024 (4)
  3. 2023 (5)
  4. 2022 (4)
  5. 2021 (5)
  6. 2020 (2)

More Years

Publications
  1. Journal of Clinical Oncology (29)
  2. Clinical Cancer Research (6)
  3. Cancer (3)
  4. Annals of Oncology (2)
  5. Clinical Genitourinary Cancer (2)
  6. Journal of Urology (2)

More Publications

Publishers
  1. American Society of Clinical Oncology (30)
  2. American Association for Cancer Research (7)
  3. Elsevier Science, Inc. (4)
  4. Wiley Blackwell (3)
  5. Elsevier BV (2)
  6. Elsevier Inc. (2)

More Publishers

Results (54)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • A novel predictive model using changes in clinical and serum biomarkers and automated quantitative imaging for mCRPC patients treated with AR-directed therapy
    Meeting Abstract

    Morris, M. J.; Flynn, J.; Zhao, B.; Anand, A.; Sjöstrand, K.; Larson, S. M.; Scher, H. I.; Regazzi, A. M.; Borzillo, G. V.; Park, A.; more...
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • Validation of automated bone scan index as a progression endpoint in two phase III studies of metastatic castration resistant prostate cancer (mCRPC) patients
    Meeting Abstract

    Knezevic, A.; Heller, G.; Sjöstrand, K.; Anand, A.; Borzillo, G.; Larson, S.; Morris, M. J.
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • Clonal hematopoiesis and clinical outcomes in metastatic castration-resistant prostate cancer patients given androgen receptor pathway inhibitors (Alliance A031201)
    Journal Article

    Jensen, J. L.; Bobek, O.; Chan, I. C. C.; Miller, B. C.; Hillman, D. W.; Heller, G.; Druley, T.; Armstrong, A. J.; Morris, M. J.; Milowsky, M. I.; more...
    Clinical Cancer Research (2024)

    Fulltext@MSK | Save
  • A phase 2 trial of ADT interruption in patients responding exceptionally to AR-pathway inhibitor in metastatic hormone-sensitive prostate cancer (A-DREAM/Alliance A032101)
    Meeting Abstract

    Choudhury, A. D.; Heller, G.; Reimers, M. A.; Laccetti, A. L.; Smieliauskas, F.; Ravi, P.; Dooley, K.; Mazza, G. L.; Gartrell, B. A.; Steen, P. D.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • PRESTO: A phase III, open-label study of intensification of androgen blockade in patients with high-risk biochemically relapsed castration-sensitive prostate cancer (AFT-19)
    Journal Article

    Aggarwal, R.; Heller, G.; Hillman, D. W.; Xiao, H.; Picus, J.; Taplin, M. E.; Dorff, T.; Appleman, L.; Weckstein, D.; Patnaik, A.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Depth of PSA nadir and subsequent PSA progression-free survival in patients (pts) with high-risk biochemically relapsed prostate cancer: Results from the phase 3 PRESTO study (AFT-19)
    Meeting Abstract

    Aggarwal, R. R.; Dooley, K.; Hillman, D. W.; Xiao, H.; Picus, J.; Taplin, M. E.; Dorff, T. B.; Appleman, L. J.; Weckstein, D. J.; Patnaik, A.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Clonal hematopoiesis in the phase 3 Alliance A031201 trial of metastatic castration resistant prostate cancer (mCRPC) treated with androgen receptor (AR)-targeted therapies
    Meeting Abstract

    Jensen, J. L.; Bobek, O.; Chan, I. C. C.; Hillman, D. W.; Heller, G.; Druley, T. E.; Morris, M. J.; Milowsky, M. I.; Beltran, H.; Bolton, K. L.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Randomized phase III study of enzalutamide compared with enzalutamide plus abiraterone for metastatic castration-resistant prostate cancer (Alliance A031201 trial)
    Journal Article

    Morris, M. J.; Heller, G.; Hillman, D. W.; Bobek, O.; Ryan, C.; Antonarakis, E. S.; Bryce, A. H.; Hahn, O.; Beltran, H.; Armstrong, A. J.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Alliance A031902 (CASPAR): A randomized phase (ph) 3 trial of enzalutamide with rucaparib/placebo in first-line metastatic castration-resistant prostate cancer (mCRPC)
    Meeting Abstract

    Rao, A.; Heller, G.; Ryan, C. J.; VanderWeele, D. J.; Lewis, L. D.; Tan, A.; Watt, C.; Chen, R. C.; Kohli, M.; Barata, P. C.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Baseline characteristics associated with PSA progression-free survival in patients (pts) with high-risk biochemically relapsed prostate cancer: Results from the phase 3 PRESTO study (AFT-19)
    Meeting Abstract

    Aggarwal, R. R.; Heller, G.; Hillman, D. W.; Xiao, H.; Picus, J.; Taplin, M. E.; Dorff, T. B.; Appleman, L. J.; Weckstein, D. J.; Patnaik, A.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save